Works matching DE "HER2 positive breast cancer"
Results: 897
An update on metastatic breast cancer New targeted therapies.
- Published in:
- Medicine Today, 2024, v. 25, n. 8, p. 51
- By:
- Publication type:
- Article
Retraction: BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways.
- Published in:
- 2025
- Publication type:
- Correction Notice
Pyrotinib-assisted whole brain radiotherapy alleviates HER2-positive advanced breast cancer and brain metastases: a prospective study in patients.
- Published in:
- Frontiers in Neurology, 2025, p. 1, doi. 10.3389/fneur.2025.1439028
- By:
- Publication type:
- Article
Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.
- Published in:
- BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-13749-1
- By:
- Publication type:
- Article
Evaluating dynamic contrast-enhanced MRI for differentiating HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy.
- Published in:
- European Journal of Medical Research, 2025, v. 30, n. 1, p. 1, doi. 10.1186/s40001-024-02188-6
- By:
- Publication type:
- Article
A Dramatic Clinical Response to Trastuzumab-Deruxtecan in a Patient with HER-2 Low Breast Cancer with Untreated Leptomeningeal Metastasis and Hydrocephalus.
- Published in:
- Current Oncology, 2025, v. 32, n. 2, p. 81, doi. 10.3390/curroncol32020081
- By:
- Publication type:
- Article
Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1559, doi. 10.3390/ijms26041559
- By:
- Publication type:
- Article
Electrochemical Modification of Polypeptides at Selenocysteine.
- Published in:
- Angewandte Chemie, 2023, v. 135, n. 50, p. 1, doi. 10.1002/ange.202313037
- By:
- Publication type:
- Article
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.
- Published in:
- NPJ Precision Oncology, 2025, v. 9, n. 1, p. 1, doi. 10.1038/s41698-025-00801-3
- By:
- Publication type:
- Article
Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study.
- Published in:
- PeerJ, 2023, p. 1, doi. 10.7717/peerj.16207
- By:
- Publication type:
- Article
多柔比星脂质体在晚期乳腺癌治疗的疗效和安全性分析.
- Published in:
- Progress in Modern Biomedicine, 2024, v. 24, n. 19, p. 3781, doi. 10.13241/j.cnki.pmb.2024.19.048
- By:
- Publication type:
- Article
Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Comprehensive Analysis of the Expression and Prognostic Value of LMAN2 in HER2+ Breast Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Early HER2-positive breast cancer arising from a fibroadenoma: a case report.
- Published in:
- Oxford Medical Case Reports, 2021, v. 2021, n. 9, p. 1, doi. 10.1093/omcr/omab083
- By:
- Publication type:
- Article
Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer.
- Published in:
- Scientific Reports, 2025, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-83302-w
- By:
- Publication type:
- Article
Author Correction: Leveraging ML for profiling lipidomic alterations in breast cancer tissues: a methodological perspective.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-74276-w
- By:
- Publication type:
- Article
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-69614-x
- By:
- Publication type:
- Article
Author Correction: Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-58710-7
- By:
- Publication type:
- Article
Characterization of Loss-of-Imprinting in Breast Cancer at the Cellular Level by Integrating Single-Cell Full-Length Transcriptome with Bulk RNA-Seq Data.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 12, p. 1598, doi. 10.3390/biom14121598
- By:
- Publication type:
- Article
Investigation of ITGB3 Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer.
- Published in:
- Biology (2079-7737), 2025, v. 14, n. 1, p. 9, doi. 10.3390/biology14010009
- By:
- Publication type:
- Article
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.
- Published in:
- Systematic Reviews, 2022, v. 11, n. 1, p. 1, doi. 10.1186/s13643-022-02134-9
- By:
- Publication type:
- Article
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00707
- By:
- Publication type:
- Article
Marginal Corneal Infiltration Following Treatment for Metastatic Breast Cancer with Triple Chemotherapy of Trastuzumab, Pertuzumab & Docetaxel.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2021, v. 12, p. 103, doi. 10.2147/LCTT.S307324
- By:
- Publication type:
- Article
PTEN as a Candidate Molecular Target that Links MVA Pathway and Anti-HER2 Therapy Resistance.
- Published in:
- IIUM Medical Journal Malaysia, 2022, v. 21, n. 3, p. 3, doi. 10.31436/imjm.v21i3.1925
- By:
- Publication type:
- Article
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer.
- Published in:
- Cellular Oncology (2211-3428), 2021, v. 44, n. 3, p. 569, doi. 10.1007/s13402-020-00583-9
- By:
- Publication type:
- Article
Prolactin: The Third Hormone in Breast Cancer.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.910978
- By:
- Publication type:
- Article
Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Multifunctional Fluorocarbon-conjugated Nanoparticles of Varied Morphologies to Enhance Diagnostic Effects in Breast Cancer.
- Published in:
- Nano Biomedicine & Engineering, 2021, v. 13, n. 1, p. 52, doi. 10.5101/nbe.v13i1.p52-61
- By:
- Publication type:
- Article
Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
- Published in:
- Annals of Medicine, 2022, v. 54, n. 1, p. 3084, doi. 10.1080/07853890.2022.2139411
- By:
- Publication type:
- Article
Are Thyroid Hormone and Tumor Cell Proliferation in Human Breast Cancers Positive for HER2 Associated?
- Published in:
- International Journal of Endocrinology, 2015, v. 2015, p. 1, doi. 10.1155/2015/765406
- By:
- Publication type:
- Article
Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-021-02098-z
- By:
- Publication type:
- Article
José Baselga M.D., Ph.D. (1959–2021) leading cancer researcher and oncologist.
- Published in:
- 2021
- By:
- Publication type:
- Announcement
MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-021-01907-9
- By:
- Publication type:
- Article
High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer.
- Published in:
- PLoS ONE, 2019, v. 14, n. 8, p. 1, doi. 10.1371/journal.pone.0221413
- By:
- Publication type:
- Article
Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
- Published in:
- PLoS ONE, 2019, v. 14, n. 4, p. 1, doi. 10.1371/journal.pone.0215894
- By:
- Publication type:
- Article
Inter-vendor variability and reproducibility of subcostal left ventricular longitudinal strain.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Triple-negative breast cancer: understanding Wnt signaling in drug resistance.
- Published in:
- Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-021-02107-3
- By:
- Publication type:
- Article
Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo.
- Published in:
- Biological Procedures Online, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s12575-023-00212-3
- By:
- Publication type:
- Article
Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.
- Published in:
- Journal of Cancer Research & Therapeutics, 2024, v. 20, n. 7, p. 1991, doi. 10.4103/jcrt.jcrt_979_24
- By:
- Publication type:
- Article
Establishment of a murine model of breast cancer expressing human epidermal growth factor receptor 2 (4T1-HER2).
- Published in:
- Journal of Cancer Research & Therapeutics, 2024, v. 20, n. 3, p. 984, doi. 10.4103/jcrt.jcrt_1303_22
- By:
- Publication type:
- Article
BREAST.
- Published in:
- Journal of Cancer Research & Therapeutics, 2024, v. 20, p. S86, doi. 10.4103/jcrt.jcrt_2121_24
- Publication type:
- Article
Efficacy and safety of a pyrotinib‑based regimen in non-small cell lung cancer patients harboring HER2 alterations: A real-world retrospective study.
- Published in:
- Journal of Cancer Research & Therapeutics, 2023, v. 19, n. 6, p. 1663, doi. 10.4103/jcrt.jcrt_1268_23
- By:
- Publication type:
- Article
Nothing is permanent except for change: Disease-free survival in cancer, time to change?
- Published in:
- Journal of Cancer Research & Therapeutics, 2021, v. 17, n. 4, p. 1132, doi. 10.4103/jcrt.JCRT_318_19
- By:
- Publication type:
- Article
Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer.
- Published in:
- Doklady Biochemistry & Biophysics, 2022, v. 507, n. 1, p. 330, doi. 10.1134/S1607672922340038
- By:
- Publication type:
- Article
A novel mutant PIK3R1<sup>EY451delinsD</sup> breast cancer patient resistant to HER2-targeted therapy treated with everolimus: a case report.
- Published in:
- Molecular Biology Reports, 2022, v. 49, n. 7, p. 6155, doi. 10.1007/s11033-022-07407-z
- By:
- Publication type:
- Article
Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer.
- Published in:
- Biotechnology Letters, 2023, v. 45, n. 3, p. 371, doi. 10.1007/s10529-022-03342-y
- By:
- Publication type:
- Article
The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib.
- Published in:
- Toxicological Sciences, 2024, v. 197, n. 1, p. 69, doi. 10.1093/toxsci/kfad099
- By:
- Publication type:
- Article
Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
- Published in:
- Biochemistry (00062979), 2024, v. 89, n. 3, p. 487, doi. 10.1134/S000629792403009X
- By:
- Publication type:
- Article